المؤلفون: Usmani, SZ, Nahi, H, Legiec, W, Grosicki, S, Vorobyev, V, Spicka, I, Hungria, V, Korenkova, S, Bahlis, NJ, Flogegard, M, Blade, J, Moreau, P, Kaiser, M, Iida, S, Laubach, J, Magen, H, Cavo, M, Hulin, C, White, D, De Stefano, V, Lantz, K, O'Rourke, L, Heuck, C, Delioukina, M, Qin, X, Nnane, I, Qi, M, Mateos, MV

المصدر: Haematologica. 107(10):2408-2417

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:151061516Test

المؤلفون: Rodriguez-Otero, P, Usmani, S, Cohen, AD, van de Donk, NWCJ, Leleu, X, Gállego Pérez-Larraya, J, Manier, S, Nooka, AK, Mateos, MV, Einsele, H, Minnema, M, Cavo, M, Derman, BA, Puig, N, Gay, F, Ho, PJ, Chng, WJ, Kastritis, E, Gahrton, G, Weisel, K, Nagarajan, C, Schjesvold, F, Mikhael, J, Costa, L, Raje, NS, Zamagni, E, Hájek, R, Weinhold, N, Yong, K, Ye, JC, Sidhana, S, Merlini, G, Martin, T, Lin, Y, Chari, A, Popat, R, Kaufman, JL

المصدر: The Lancet. Oncology. 25(5):e205-e216

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:238697166Test

المؤلفون: Carolina Terragna, Andrea Poletti, Vincenza Solli, Marina Martello, Elena Zamagni, Lucia Pantani, Enrica Borsi, Ilaria Vigliotta, Gaia Mazzocchetti, Silvia Armuzzi, Barbara Taurisano, Nicoletta Testoni, Giulia Marzocchi, Ajsi Kanapari, Ignazia Pistis, Paola Tacchetti, Katia Mancuso, Serena Rocchi, Ilaria Rizzello, Michele Cavo

المصدر: Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)

مصطلحات موضوعية: Science

الوصف: Abstract The complexity of Multiple Myeloma (MM) is driven by several genomic aberrations, interacting with disease-related and/or -unrelated factors and conditioning patients’ clinical outcome. Patient’s prognosis is hardly predictable, as commonly employed MM risk models do not precisely partition high- from low-risk patients, preventing the reliable recognition of early relapsing/refractory patients. By a dimensionality reduction approach, here we dissect the genomic landscape of a large cohort of newly diagnosed MM patients, modelling all the possible interactions between any MM chromosomal alterations. We highlight the presence of a distinguished cluster of patients in the low-dimensionality space, with unfavorable clinical behavior, whose biology was driven by the co-occurrence of chromosomes 1q CN gain and 13 CN loss. Presence or absence of these alterations define MM patients overexpressing either CCND2 or CCND1, fostering the implementation of biology-based patients’ classification models to describe the different MM clinical behaviors.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2041-1723Test

الوصول الحر: https://doaj.org/article/b0670f38bd1042f68b22b11a9e85ac10Test

المؤلفون: Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, Ugo De Giorgi, Sebastiano Buti, Luca Galli, Giuseppe Fornarini, Paolo Andrea Zucali, Melanie Claps, Silvia Chiellino, Ilaria Zampiva, Stefania Pipitone, Riccardo Ricotta, Mariella Sorarù, Veronica Mollica, Marianna Tudini, Lucia Fratino, Veronica Prati, Orazio Caffo, Francesco Atzori, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Marilena Di Napoli, Andrea Malgeri, Emanuele Naglieri, Alessio Signori, Giuseppe Luigi Banna, Pasquale Rescigno, Linda Cerbone, Lorenzo Antonuzzo, Giandomenico Roviello

المصدر: Frontiers in Immunology, Vol 15 (2024)

مصطلحات موضوعية: renal cell carcinoma, bone metastases, immunotherapy, sodium levels, efficacy outcomes, Immunologic diseases. Allergy, RC581-607

الوصف: BackgroundImmune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prognostic role of natremia in pretreated RCC patients with BMs receiving immunotherapy.Materials and methodsThis retrospective multicenter study included RCC patients with BMs receiving nivolumab as second-line therapy or beyond. Inclusion criteria involved baseline sodium levels (pre-ICI) and sodium levels after 4 weeks of nivolumab initiation (post-ICI). The population was divided into two groups based on the median value, and response rates, progression-free survival (PFS), and overall survival (OS) were assessed.ResultsAmong 120 eligible patients, those with pre-treatment sodium levels ≥140 mEq/L showed longer OS (18.7 vs. 12.0 months, p=0.04). Pre-treatment sodium levels ≥140 mEq/L were associated with better OS compared to levels

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1361010/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/e1a5d05c7cd04f7d95a2a3e615d48926Test

المؤلفون: Giulia Corradi, Dorian Forte, Gianluca Cristiano, Andrea Polimeno, Marilena Ciciarello, Valentina Salvestrini, Lorenza Bandini, Valentina Robustelli, Emanuela Ottaviani, Michele Cavo, Darina Ocadlikova, Antonio Curti

المصدر: Frontiers in Immunology, Vol 15 (2024)

مصطلحات موضوعية: acute myeloid leukemia, immune system, venetoclax, hypomethylating agents, immune checkpoints receptors, immune checkpoint inhibitors (ICIs), Immunologic diseases. Allergy, RC581-607

الوصف: Acute myeloid leukemia (AML) is an aggressive heterogeneous disease characterized by several alterations of the immune system prompting disease progression and treatment response. The therapies available for AML can affect lymphocyte function, limiting the efficacy of immunotherapy while hindering leukemia-specific immune reactions. Recently, the treatment based on Venetoclax (VEN), a specific B-cell lymphoma 2 (BCL-2) inhibitor, in combination with hypomethylating agents (HMAs) or low-dose cytarabine, has emerged as a promising clinical strategy in AML. To better understand the immunological effect of VEN treatment, we characterized the phenotype and immune checkpoint (IC) receptors’ expression on CD4+ and CD8+ T cells from AML patients after the first and second cycle of HMA in combination with VEN. HMA and VEN treatment significantly increased the percentage of naïve CD8+ T cells and TIM-3+ CD4+ and CD8+ T cells and reduced cytokine-secreting non-suppressive T regulatory cells (Tregs). Of note, a comparison between AML patients treated with HMA only and HMA in combination with VEN revealed the specific contribution of VEN in modulating the immune cell repertoire. Indeed, the reduction of cytokine-secreting non-suppressive Tregs, the increased TIM-3 expression on CD8+ T cells, and the reduced co-expression of PD-1 and TIM-3 on both CD4+ and CD8+ T cells are all VEN-specific. Collectively, our study shed light on immune modulation induced by VEN treatment, providing the rationale for a novel therapeutic combination of VEN and IC inhibitors in AML patients.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1386517/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/a5d55294093e4929a53b57474c48442fTest

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Flavia Bigi, Paola Tacchetti, Alessandro Giorgi, Gaia Mazzocchetti, Vincenza Solli, Simona Barbato, Barbara Sinigaglia, Elena Campanini, Emanuele Favero, Marco Talarico, Michele Puppi, Ilaria Rizzello, Serena Rocchi, Katia Mancuso, Lucia Pantani, Michele Cavo, Elena Zamagni

المصدر: Frontiers in Hematology, Vol 3 (2024)

مصطلحات موضوعية: multiple myeloma, mobilization, hematopoietic stem cell (HSC), daratumumab, plerixafor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: The impact of daratumumab on CD34+ hematopoietic stem cell (HSC) mobilization has recently been a matter of concern. To address this issue, we compared CD34+ HSC-related outcomes in patients with multiple myeloma treated with daratumumab-based quadruplets (N = 44) and bortezomib/thalidomide/dexamethasone (N = 50) before cyclophosphamide-based mobilization. Plerixafor was more often required in the daratumumab group (52% vs. 20%, p = 0.002) and, despite a lower total yield, retained its efficacy in boosting HSC harvesting (+90% vs. +79%, p = 0.463). As a result, the same proportion of patients reached their planned collection goal in the two groups, suggesting its potential to overcome the interference of daratumumab on HSC mobilization. No clinically significant differences were observed in the immediate post-autologous HSC transplant interval in the two groups.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/frhem.2024.1386973/fullTest; https://doaj.org/toc/2813-3935Test

الوصول الحر: https://doaj.org/article/950b5b65be544c078de9b75b3a23a37dTest

المؤلفون: Maria Victoria Mateos, Katja Weisel, Evangelos Terpos, Sossana Delimpasi, Efstathios Kastritis, Elena Zamagni, Michel Delforge, Enrique Ocio, Eirini Katodritou, Francesca Gay, Alessandra Larocca, Xavier Leleu, Paula Rodriguez Otero, Fredik Schjesvold, Michele Cavo, Meletios A. Dimopoulos

المصدر: Haematologica, Vol 999, Iss 1 (2024)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

الوصف: Not available.

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/11470Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/d32b963c3bd94ba795f5046d7984d202Test

المؤلفون: Paul G. Richardson, Aurore Perrot, Jesus San Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Shang-Yi Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, Mony Chenda Morisse, Kenneth C. Anderson

المصدر: Haematologica, Vol 999, Iss 1 (2024)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

الوصف: The primary and pre-specified updated analyses of ICARIA-MM (NCT02990338) demonstrated improved progression-free survival and a benefit in overall survival (OS) was reported with the addition of isatuximab, an anti-CD38 monoclonal antibody, to pomalidomide–dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma. Here, we report the final OS analysis. This multicenter, randomized, open-label, phase 3 study included patients who had received and failed ≥2 previous therapies, including lenalidomide and a proteasome inhibitor. Between January 10, 2017, and February 2, 2018, 307 patients were randomized (1:1) to isatuximab–pomalidomide– dexamethasone (Isa-Pd; n = 154) or Pd (n = 153), stratified based on age (3). At data cutoff for the final OS analysis after 220 OS events (January 27, 2022), median follow-up duration was 52.4 months. Median OS (95% confidence interval) was 24.6 months (20.3–31.3 months) with Isa-Pd and 17.7 months (14.4–26.2 months) with Pd (hazard ratio = 0.78; 95% CI, 0.59–1.02; 1-sided P = 0.0319). Despite subsequent daratumumab use in the Pd group and its potential benefit on PFS in the first subsequent therapy line, median PFS2 was significantly longer with Isa-Pd vs. Pd (17.5 vs. 12.9 months; log-rank 1-sided P = 0.0091). In this analysis, Isa-Pd continued to be efficacious and well tolerated after follow-up of approximately 52 months, contributing to a clinically meaningful, 6.9-month improvement in median overall survival in patients with relapsed/refractory multiple myeloma.

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/11432Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/2cdeb822507640969679ff3be53cc866Test